Revisiting an old friend - pimecrolimus

K. A. Papp  MD, PhD
Probity Medical Research
KAP is a consultant, investigator, speaker and advisory board member for

- Astellas
- GSK
- Leo
- Valeant
Warning

some content may not be suitable to all audiences
CyA
Pimecrolimus (Elidel) SDZ ASM
Macrolactam
isolated from Streptomyces hygroscopiius var. ascomyceticus
works through the FK-BP-12 inhibiting the dephosphorylation of NF-AT

Grassberger M, Steinhoff M, Schneider D, Luger TA. Exp Dermatol 2004
What are you going to do?
Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial


BJD 2005

Pbo, 10, 20, 30 mg b.d. x 12 weeks

Mean % change pasi from baseline
3.1%
22.2%
51.3%
54.0%
Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial

K. Wolff, C. Fleming,* J. Hanifin,† K. Papp,‡ S. Reitamo,§ M. Rustin,¶ N. Shear,** W. Silny,†† N. Korman,‡‡ I. Marks, §§ R. Cherill, §§ S. Emady-Azar §§§ and C. Paul §§§ for the Multicentre Investigator Group

BJD 2005

Pbo, 10, 20, 30 mg b.d.
Mean % reduction EASI wk 12
Optimizing AD Therapy with TCIs

Latest Clinical Trial- 2015
• PIM 1% BID, emollient BID as needed
• Age group ≥3–<12 months
• Two arms: Pimecrolimus (n = 1205) & TCS (n = 1213)
• Open-label, randomized, parallel group 5 yr
Long-term efficacy of PIM compared with TCS- Face

Sigurgeirsson and al.; Safety and Efficacy of Pimecrolimus in Atopic Dermatitis: A 5-Year Randomized Trial; PEDIATRICS Volume 135, number 4, April 2015
Concomitant use with steroids

Pimecrolimus is associated with a steroid-sparing effect
- PIM group used TCSs for a median of only 7 days compared with 178 days in the other group.
- 36% of patients in PIM group did not use any TCS

Adapted from Sigurgeirsson, et al. Atopic dermatitis (AD) primarily affects infants and young children. A total of 2,418 infants were enrolled in this 5-year open-label study. Infants were randomized in a 1:1 ratio to either PIM (n=1,209) or TCSs (n=1,213). The primary objective was to compare safety; the secondary objective was to document PIM’s long-term efficacy.
Off Label

Do not try this at home

We are professionals with specialized training
Off label use

**Allergic Contact Dermatitis**

- Alomar A, Puig L, Gallardo CM, et al. Topical tacrolimus 0.1% ointment (protopic) reverses nickel contact dermatitis elicited by allergen challenge to a similar degree to mometasone furoate 0.1% with greater suppression of late erythema. *Contact Dermatitis*. 2003 Oct;49(4):185–8.
Off label use

- **Cutaneous Lupus**


Off label use

• Lichen Planus


Off label use

• LSA


Off label use

Psoriasis

• Ortonne JP, van de Kerkhof PC, Prinz JC, et al. 0.3% Tacrolimus gel and 0.5% Tacrolimus cream show efficacy in mild to moderate plaque psoriasis: Results of a randomized, open-label, observer-blinded study. Acta Derm Venereol. 2006 86(1):29–33.
• Liao YH, Chiu HC, Tseng YS, et al. Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Br J Dermatol. 2007 Nov;157(5):1005–12.
Off label use

Seborrhea

Off label use

Vitiligo

Off label use

- Lichen Striatus
